Archive
13 stories across regenerative medicine.
The FDA has authorized the first OTC continuous glucose monitor, aimed specifically at children aged two and older, marking a significant step in diabetes management.
The FDA has approved the first generic version of Xofluza, a breakthrough single-dose influenza treatment, heralding potential shifts in treatment accessibility and affordability.
DeepHealth has received FDA 510(k) clearance for its AI-based tool designed to enhance breast ultrasound imaging, which is a significant advancement in diagnostic technology.
Total Flow Medical's femoral arterial cannula has received FDA 510(k) clearance, enhancing options for cardiopulmonary bypass procedures.